M istaken ideas about licensing persist in spite of clarifications by, for instance, the Royal College of Paediatrics and Child Health 1 and the British Paediatric Association. 2 For instance, consultants frequently voice concerns as to whether the prescription of an unlicensed drug will render them liable to disciplinary or litigious action. A licence is a marketing authorisation issued by a national regulatory body (Medicines and Healthcare products Regulatory Agency (MHRA) in the UK; European Medicines Agency (EMEA) for the European Union; Food and Drug Administration (FDA) in the USA) enabling a pharmaceutical company to market its product. It is granted following an application by the company which must be supported by data on safety and efficacy relevant to a particular clinical indication and a particular age group. The application is paid for by the company, directly through a fee, and indirectly through the cost of clinical trials that are required to yield safety and efficacy data. The decision to apply for a licence will therefore be influenced by commercial considerations of whether the cost of obtaining a licence will be recoverable by volume of sales.
The use of licensed medicines outside the condition of the licence is referred to as ''off label'', an expression that derives from a term used in the US authorisation process: FDA approved product labelling. Some medicines given to children, such as melatonin, have never been considered for a licence and are thus unlicensed.
OFF LABEL PRESCRIBING FOR CHILDREN
Various studies have shown that prescribing unlicensed or off label medication is more frequent for children than for adults. 3 Many medicines prescribed for children and adolescents are either not licensed for under 18 year olds (for example, amiloride), the route of administration is not the one for which it has been approved (for example, oral midazolam), or the product is not licensed at all (for example, caffeine). In addition, there are also compounds that are licensed for children, but not for adults (for example, methylphenidate).
The prescription of off label and unlicensed medicines for children applies especially in neonatal medicine and hospital practice, 4-8 but it is also quite prevalent in the community, where the much larger numbers of children mean that it is a major issue. [9] [10] [11] [12] Data from selected studies are shown in table 1.
THE SITUATION IN THE UK
Doctors are allowed to prescribe off label. In the UK, this is covered by the Medicines Act 1968 and the EC Pharmaceutical Directive 89/341/EEC which outlines requirements of the EEC pharmaceutical legislation relating to medicinal products for human use. 13 However, the recent usage by the MHRA of terms such as ''contraindicated'' in its statement about the use of drugs (for example, selective serotonin reuptake inhibitors (SSRIs)) in children seems to intrude into medical practice rather than pharmaceutical marketing regulation.
14 Managing authorities, such as NHS Trusts or individual practices, on the other hand, may issue guidelines discouraging or even prohibiting the use of off label or unlicensed medications. Individual doctors may fear litigation by parents if there are adverse reactions to such medicines. Indeed, adverse reactions are more common than with licensed drugs, partly because dosing schedules for drugs developed with reference to adult populations have often not been assessed for children. 15 In some countries reimbursement of off label or unlicensed prescriptions costs by medical insurance may be refused. 4 
FUTURE TRENDS
The current situation regarding the licensing of medicines for children is a profoundly unsatisfactory state of affairs both for children and their doctors. In the US, the FDA has taken several steps to improve matters, including an initiative which requires pharmaceutical companies to review their data to see if adult derived data on effectiveness or dosing can be extrapolated to children. In a paper reviewing this issue it was pointed out that there are occasions where the reverse may apply-approval for a drug indication in childhood may need to be extended into adulthood. 16 Attention deficit/hyperactivity disorder (ADHD) is a clear instance of this. It is becoming increasingly recognised that as new products come to market, regulatory agencies internationally are requiring pharmaceutical companies to obtain rigorous and comprehensive paediatric data as part of their submission, and rightly so.
For the present, it is accepted that off label and off licence prescribing in paediatric practice is acceptable and necessary when no suitable alternative to the required treatment is available. 17 Although ultimate legal responsibility lies with the prescriber, the prescription of these treatments does not constitute a breach of duty as long as the prescriber can rely on information and guidance from a respected body of medical opinion. 17 In the UK, the publication Medicines for Children, 1 produced by the Royal College of Paediatrics and Child Health, is generally cited as representing the respected body of knowledge, because broad consensus among a large number of UK paediatricians was obtained as to its content and recommendations. 
